Home > Annual Financials > ORCHID PHARMA

ORCHID PHARMA Financial Statement Analysis
[BOM: 524372|NSE : ORCHPHARMA]

The Revenues of ORCHID PHARMA have increased by 19.00% YoY .
The Earnings Per Share (EPS) of ORCHID PHARMA has increased by Positive YoY.
REVENUES
OPERATING MARGIN
PROFIT AFTER TAX
EPS
ROCE

ORCHID PHARMA Last 5 Annual Financial Results
[BOM: 524372|NSE : ORCHPHARMA]

ConsolidatedMar2023
Mar2022
Mar2021
Mar2020
Mar2019
Revenues ₹666 Cr₹560 Cr₹450 Cr₹484 Cr₹600 Cr
Expenses ₹582 Cr₹505 Cr₹399 Cr₹515 Cr₹612 Cr
Operating Profit (Excl OI) ₹84 Cr₹55 Cr₹51 Cr₹-31 Cr₹-12 Cr
Other Income ₹19 Cr₹9.00 Cr₹15 Cr₹24 Cr₹17 Cr
Interest ₹33 Cr₹33 Cr₹52 Cr₹6.23 Cr₹6.69 Cr
Depreciation ₹55 Cr₹87 Cr₹109 Cr₹118 Cr₹130 Cr
Profit Before Tax ₹55 Cr₹-57 Cr₹-95 Cr₹-131 Cr₹69 Cr
Profit After Tax ₹55 Cr₹-57 Cr₹-95 Cr₹-131 Cr₹69 Cr
Consolidated Net Profit ₹46 Cr₹-1.95 Cr₹-117 Cr₹-131 Cr₹70 Cr
Earnings Per Share (Rs)₹11.35₹-0.48₹-28.55₹-32.11₹7.80
PAT Margin (%)8.30-10.17-21.16-27.0911.57
ROE(%)8.27-8.75-13.43-423.170.00
ROCE(%)9.11-2.32-3.53-6.473.08
Total Debt/Equity(x)0.480.410.690.74-4.59

Key Financials

Market Cap : ₹ 5,550.6 Cr
Revenue (TTM) : ₹ 812.2 Cr
Net Profit(TTM) : ₹ 126.9 Cr
EPS (TTM) : ₹ 25.0
P/E (TTM) : 43.7

Industry Peers & Returns1W1M1Y
ORCHID PHARMA 8.6% -12.4% 175.7%
SUN PHARMACEUTICAL INDUSTRIES 3% 2.3% 68.2%
CIPLA 2.5% 0.4% 71.7%
DR REDDYS LABORATORIES -0.2% -4.9% 40.3%
ZYDUS LIFESCIENCES 5% 10.4% 109.1%
DIVIS LABORATORIES -1.6% -7% 23.8%
MANKIND PHARMA NA NA NA
TORRENT PHARMACEUTICALS 2.9% -2.2% 69%
LUPIN 2.8% 0% 147.8%


ORCHID PHARMA Revenues
[BOM: 524372|NSE : ORCHPHARMA]

Y-o-Y

19.00 %

5 Yr CAGR

2.64 %

Years Revenues % Change
Mar2023 ₹666 Cr
19.00
Mar2022 ₹560 Cr
24.33
Mar2021 ₹450 Cr
-6.97
Mar2020 ₹484 Cr
-19.36
Mar2019 ₹600 Cr -


ORCHID PHARMA Operating Profit
[BOM: 524372|NSE : ORCHPHARMA]

Y-o-Y

54.45 %

5 Yr CAGR

Positive

Years Operating Profit % Change
Mar2023 ₹84 Cr
54.45
Mar2022 ₹55 Cr
7.73
Mar2021 ₹51 Cr
Positive
Mar2020 ₹-31 Cr
Negative
Mar2019 ₹-12 Cr -

Operating Margins
Y-o-Y

29.85 %

5 Yr CAGR

Positive

Years Operating Margin% % Change
Mar2023 12.66%
29.85
Mar2022 9.75%
-13.41
Mar2021 11.26%
Positive
Mar2020 -6.45%
Negative
Mar2019 -1.97% -

ORCHID PHARMA Profit After Tax
[BOM: 524372|NSE : ORCHPHARMA]

Y-o-Y

Positive

5 Yr CAGR

-9.91 %

Years Profit After Tax % Change
Mar2023 ₹46 Cr
Positive
Mar2022 ₹-1.95 Cr
Negative
Mar2021 ₹-117 Cr
Negative
Mar2020 ₹-131 Cr
Negative
Mar2019 ₹70 Cr -

PAT Margins
Y-o-Y

Positive

5 Yr CAGR

-7.97 %

Years PAT Margin(%) % Change
Mar2023 8.3 %
Positive
Mar2022 -10.17 %
Negative
Mar2021 -21.16 %
Negative
Mar2020 -27.09 %
Negative
Mar2019 11.57 % -

ORCHID PHARMA Earnings Per Share (EPS)
[BOM: 524372|NSE : ORCHPHARMA]

Y-o-Y

Positive

5 Yr CAGR

9.83 %

Years EPS % Change
Mar2023 ₹11
Positive
Mar2022 ₹-0.48
Negative
Mar2021 ₹-29
Negative
Mar2020 ₹-32
Negative
Mar2019 ₹7.80 -

ORCHID PHARMA Return on Capital Employed (ROCE)
[BOM: 524372|NSE : ORCHPHARMA]

Y-o-Y

Positive

5 Yr CAGR

31.14 %

Years ROCE % Change
Mar2023 9.11%
Positive
Mar2022 -2.32%
Negative
Mar2021 -3.53%
Negative
Mar2020 -6.47%
Negative
Mar2019 3.08% -

ORCHID PHARMA Share Price vs Sensex

Current Share Price : ₹1,094.8
Current MarketCap: ₹ 5,550.6 Cr
Updated EOD on :Apr 16,2024

Share Price Returns(%) 1 Week 1 Month 1 Year
ORCHID PHARMA

8.6%

-12.4%

175.7%

SENSEX

-2.4%

-1%

21.3%

ORCHID PHARMA related INDICES

No BSE index found!
No NSE index found

You may also like the below Video Courses


FAQ about ORCHID PHARMA Financials


How the annual revenues of ORCHID PHARMA have changed ?

The Revenues of ORCHID PHARMA have increased by 19.00% YoY .

How the Earnings per Share (EPS) of ORCHID PHARMA have changed?

The Earnings Per Share (EPS) of ORCHID PHARMA has increased by Positive YoY .